MDT
$86.16-0.71 (-0.82%)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Recent News
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
FDA Clears MiniMed Flex Pump As Medtronic Valuation Debate Continues
MiniMed, the recently spun-out diabetes business of Medtronic, has received FDA clearance for its MiniMed Flex insulin pump. The MiniMed Flex is a next-generation, smartphone-controlled pump that is materially smaller than prior MiniMed devices. MiniMed plans a commercial launch of MiniMed Flex following this clearance, adding a new product to the broader Medtronic (NYSE:MDT) ecosystem. For investors tracking Medtronic, the FDA clearance for MiniMed Flex sits squarely in the core of what...
Medtronic (MDT) Down 11.5% Since Last Earnings Report: Can It Rebound?
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MiniMed gets FDA nod for smaller insulin pump
MiniMed Flex is a smartphone-controlled insulin pump about half the size of MiniMed’s previous device. It’s the company’s first launch since separating from Medtronic in early March.